Cargando…
Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs
PURPOSE: To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimal response to previous anti-vascular endothelial growth factor (anti-VEGF) injections. METHODS: A prospective interventional case series study recruited patients from a single center diagnosed...
Autores principales: | Ibrahim, Walid S., Eldaly, Zeiad H., Saleh, Mohamed G., Rateb, Mahmoud F., Aldoghaimy, Ahmed H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Ophthalmological Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462479/ https://www.ncbi.nlm.nih.gov/pubmed/30977321 http://dx.doi.org/10.3341/kjo.2018.0037 |
Ejemplares similares
-
Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab
por: Xing, Peiyu, et al.
Publicado: (2023) -
One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
por: Abouhussein, Mahmoud Alaa, et al.
Publicado: (2021) -
Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017) -
Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
por: Mira, Filipe, et al.
Publicado: (2017) -
Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion
por: Spooner, Kimberly, et al.
Publicado: (2020)